Skip to main content
Equibles

GLAXO · GlaxoSmithKline Pharmaceuticals Limited

Use GLAXO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAXO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,655.60 INR -72.10 (-2.64%) At close · Nov 12
Rebalance outlook locked
Market Cap
449.87B INR
Shares
169.41M
Volume · Nov 12 64.49K Avg daily vol (3M) 120.61K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close2,655.60 INR Open2,722.50 INR Day2,652.10–2,727.90 INR 52W close2,103.20–3,106.3999 INR Avg vol 30d86K Last earningsNov 4, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 4
Earnings call
Revenue rises 21% as Blenrep launch nears

GlaxoSmithKline Pharmaceuticals Limited reported Q2 revenue of INR1,180 crores, up 21%, and PAT growth of 33%. Management maintained its INR8,000 crores revenue aspiration by 2031 and planned the Blenrep launch in the December quarter.

6 source passages
From the management at GlaxoSmithKline Pharmaceuticals Limited, we have Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited; and Mr. Ronojit Biswas, Chief Financial Officer, GlaxoSmithKline Pharmaceuticals Limited. the results that were just announced for the Q2 of 2027 our, revenues during the September quarter increased 21% versus the previous year quarter to INR1,180 crores. Moving to PAT, profit after tax for the quarter grew 33%. the INR8,000 crores is an aspiration by 2031 We're very excited about, our launch of Blenrep, which is going to happen in the December quarter. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲17.9% 9.49B INR 2.30B INR '25 Q3 ▲4.8% 9.74B INR 0 INR '25 Q4 ▼1.2% 8.05B INR 0 INR '26 Q1 ▼3.1% 9.80B INR 0 INR '26 Q2 ▲9.7% 10.41B INR 0 INR '26 Q3 ▲2.1% 9.95B INR 2.78B INR '26 Q4 ▲16.6% 9.38B INR 2.37B INR '27 Q1 LATEST ▲20.8% 11.84B INR 0 INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 2,103.20 INR Now 2,655.60 INR · 55% Range high 3,106.3999 INR
vs 200-day avg +5% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:GLAXO +6.2% +4.6% +14.4% +6.5% +7.4%

Exchange listing

Market
XNSE
Ticker
GLAXO
ISIN
INE159A01016
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.india-pharma.gsk.com/
Investor relations
https://india-pharma.gsk.com/en-in/investors/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-05-29 57.00 INR
2025-05-30 42.00 INR
2024-11-07 12.00 INR
2024-05-31 32.00 INR
2023-06-30 32.00 INR
2022-07-07 90.00 INR
2021-07-19 30.00 INR
2020-07-17 40.00 INR
2019-07-11 20.00 INR
2018-07-13 17.50 INR
2017-07-14 15.00 INR
2016-07-15 25.00 INR
2014-04-03 25.00 INR
2013-04-04 25.00 INR
2012-03-29 22.50 INR
2011-03-14 20.00 INR
2010-03-10 15.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-04 Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-08-03 Transcript
    Earnings Call
  • Earnings call · Q4 2026 2026-05-13 Transcript
    Earnings Call